指南的相似性与差异性:妊娠期高血压国际临床实践指南的系统综述
该系统综述纳入2009至2019年以英、法、荷、德文发表的17部妊娠期高血压临床实践指南,其中15部(4部国际)被评为「临床有用」并提取推荐。指南在血压测量、蛋白尿筛查、子痫前期定义、阿司匹林预防、严重高血压治疗、硫酸镁使用等方面推荐一致,但在子痫前期定义成分、风险识别与阿司匹林给药、钙剂价值、血压正常化、胎儿神经保护及分娩时机方面存在不一致。
要点
- 15部指南推荐自动血压测量并使用经妊娠和子痫前期验证的装置。
- 推荐蛋白尿试纸筛查后以尿蛋白肌酐比或24小时尿定量确认。
- 严重高血压治疗常用静脉拉贝洛尔、口服硝苯地平或静脉肼屈嗪。
核心结论
- 一致的推荐应被实施和审核,不一致之处应成为研究重点。
研究设计与样本
- 系统综述,检索2009至2019年以英文、法文、荷兰文或德文发表的国家和国际妊娠期高血压临床实践指南,前瞻性注册号CRD42019123787。
- 共识别17部临床实践指南(其中4部为国际指南),15部被评为「临床有用」并提取推荐。
- 由2名作者独立使用AGREE II工具评分并提取数据,分歧通过共识解决。
主要发现
- AGREE II最高分来自政府组织,且评分随时间改善。
- 一致推荐包括:自动血压测量使用经妊娠和子痫前期验证的装置;蛋白尿试纸筛查后以尿蛋白肌酐比或24小时尿定量确认;子痫前期广义定义(包括蛋白尿和母体终末器官功能障碍,含头痛和视觉症状及血小板、肌酐或肝酶实验室异常)并认识到产后可加重;阿司匹林预防子痫前期;严重高血压治疗常用静脉拉贝洛尔、口服硝苯地平或静脉肼屈嗪;非严重高血压治疗(如进行)用口服拉贝洛尔(尤其)、甲基多巴或硝苯地平,并推荐反对使用肾素-血管紧张素-醛固酮抑制剂;硫酸镁用于子痫治疗及「严重」子痫前期女性的预防;早产前使用产前糖皮质激素但非HELLP综合征;子痫前期足月分娩;关注常规产程和分娩护理但避免麦角新碱;认识到长期健康并发症发生率增加,需生活方式改变和危险因素修正。
- 不一致领域包括:广义子痫前期定义的成分(特别是呼吸和胃肠道症状、胎儿表现和生物标志物)、严重子痫前期的构成、以及定义是否有用(因为目前要求蛋白尿的指南所定义的严重子痫前期,在多数其他指南中已定义为任何子痫前期);妊娠早期子痫前期风险识别及阿司匹林给药(多变量模型联合生物标志物和超声与临床风险标志物可显著降低早产子痫前期发生率);钙剂加入阿司匹林预防子痫前期的价值(尤其低摄入且子痫前期风险增加女性);新兴推荐即使无合并症也用降压药使血压正常化;无「严重」子痫前期时硫酸镁用于胎儿神经保护;慢性高血压、妊娠期高血压和早产子痫前期的分娩时机。
关键数值与推荐
- 推荐自动血压测量并使用经妊娠和子痫前期验证的装置。
- 推荐蛋白尿试纸筛查后以尿蛋白肌酐比或24小时尿收集定量确认。
- 推荐阿司匹林预防子痫前期。
- 推荐严重高血压治疗常用静脉拉贝洛尔、口服硝苯地平或静脉肼屈嗪。
- 推荐非严重高血压治疗(如进行)用口服拉贝洛尔(尤其)、甲基多巴或硝苯地平,并推荐反对使用肾素-血管紧张素-醛固酮抑制剂。
临床怎么用
- 一致的推荐应被实施和审核。
- 不一致之处应成为研究重点。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: This study aimed to review pregnancy hypertension clinical practice guidelines to inform international clinical practice and research priorities. STUDY ELIGIBILITY CRITERIA: Relevant national and international clinical practice guidelines, 2009-19, published in English, French, Dutch or German. STUDY APPRAISAL AND SYNTHESIS METHODS: Following published methods and prospective registration (CRD42019123787), a literature search was updated. CPGs were identified by 2 authors independently who scored quality and usefulness for practice (Appraisal of Guidelines for Research and Evaluation II instrument), abstracted data, and resolved any disagreement by consensus. RESULTS: Of note, 15 of 17 identified clinical practice guidelines (4 international) were deemed "clinically useful" and had recommendations abstracted. The highest Appraisal of Guidelines for Research and Evaluation II scores were from government organizations, and scores have improved over time. The following were consistently recommended: (1) automated blood pressure measurement with devices validated for pregnancy and preeclampsia, reflecting increasing recognition of the prevalence of white-coat hypertension and the potential usefulness of home blood pressure monitoring; (2) use of dipstick proteinuria testing for screening followed by quantitative testing by urinary protein-to-creatinine ratio or 24-hour urine collection; (3) key definitions and most aspects of classification, including a broad definition of preeclampsia (which includes proteinuria and maternal end-organ dysfunction, including headache and visual symptoms and laboratory abnormalities of platelets, creatinine, or liver enzymes) and a recognition that it can worsen after delivery; (4) preeclampsia prevention with aspirin; (5) treatment of severe hypertension, most commonly with intravenous labetalol, oral nifedipine, or intravenous hydralazine; (6) treatment for nonsevere hypertension when undertaken, with oral labetalol (in particular), methyldopa, or nifedipine, with recommendations against the use of renin-angiotensin-aldosterone inhibitors; (7) magnesium sulfate for eclampsia treatment and prevention among women with "severe" preeclampsia; (8) antenatal corticosteroids for preterm birth but not hemolysis, elevated liver enzymes, and low platelet count syndrome; (9) delivery at term for preeclampsia; (10) a focus on usual labor and delivery care but avoidance of ergometrine; and (11) an appreciation that long-term health complications are increased in incidence, mandating lifestyle change and risk factor modification. Lack of uniformity was seen in the following areas: (1) the components of a broad preeclampsia definition (specifically respiratory and gastrointestinal symptoms, fetal manifestations, and biomarkers), what constitutes severe preeclampsia, and whether the definition has utility because at present what constitutes severe preeclampsia by some guidelines that mandate proteinuria now defines any preeclampsia for most other clinical practice guidelines; (2) how preeclampsia risk should be identified early in pregnancy, and aspirin administered for preeclampsia prevention, because multivariable models (with biomarkers and ultrasonography added to clinical risk markers) used in this way to guide aspirin therapy can substantially reduce the incidence of preterm preeclampsia; (3) the value of calcium added to aspirin for preeclampsia prevention, particularly for women with low intake and at increased risk of preeclampsia; (4) emerging recommendations to normalize blood pressure with antihypertensive agents even in the absence of comorbidities; (5) fetal neuroprotection as an indication for magnesium sulfate in the absence of "severe" preeclampsia; and (6) timing of birth for chronic and gestational hypertension and preterm preeclampsia. CONCLUSION: Consistent recommendations should be implemented and audited. Inconsistencies should be the focus of research.
引用
- Scott G, Gillon TE, Pels A, et al. Guidelines-similarities and dissimilarities: a systematic review of international clinical practice guidelines for pregnancy hypertension. Am J Obstet Gynecol. 2020. PMID: 32828743. doi:10.1016/j.ajog.2020.08.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。